Liquid biopsy is a promising tool to predict benefit from anti–epidermal growth factor receptor (EGFR) retreatment in metastatic colorectal cancer patients. However, this technique is far from ready for routine clinical practice. Therefore, we identified 86 patients in a real-life database of 5530 patients to explore clinical features expected to predict benefit from anti-EGFR retreatment; however, none of these factors was predictive of response to anti-EGFR retreatment.
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis
Scartozzi M.;
2020-01-01
Abstract
Liquid biopsy is a promising tool to predict benefit from anti–epidermal growth factor receptor (EGFR) retreatment in metastatic colorectal cancer patients. However, this technique is far from ready for routine clinical practice. Therefore, we identified 86 patients in a real-life database of 5530 patients to explore clinical features expected to predict benefit from anti-EGFR retreatment; however, none of these factors was predictive of response to anti-EGFR retreatment.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
rossini2020.pdf
Solo gestori archivio
Tipologia:
versione post-print (AAM)
Dimensione
518.76 kB
Formato
Adobe PDF
|
518.76 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
